Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ATSN-201

Phase 3Biologic

AAtsena Therapeutics Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

RetinoschisisRecruiting

RetinoschisisPhase 3

Recruiting

Timeline

Expected Milestones

Q2 2033

Phase 3Recruiting

Retinoschisis

NCT05878860

Clinical

Trials by Indication[1]

Retinoschisis1 trial

A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects With RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)

Recruiting·AAtsena Therapeutics Inc.·Phase 3·NCT05878860·97 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ATSN-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATSN-201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATSN-201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Atsena Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: AAtsena Therapeutics Inc.

Related News